Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Revenue (2018 - 2025)

10x Genomics' Revenue history spans 8 years, with the latest figure at $166.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 0.61% year-over-year to $166.0 million; the TTM value through Dec 2025 reached $642.8 million, up 5.25%, while the annual FY2025 figure was $642.8 million, 5.25% up from the prior year.
  • Revenue for Q4 2025 was $166.0 million at 10x Genomics, up from $149.0 million in the prior quarter.
  • Across five years, Revenue topped out at $184.0 million in Q4 2023 and bottomed at $105.8 million in Q1 2021.
  • The 5-year median for Revenue is $147.9 million (2023), against an average of $144.0 million.
  • The largest annual shift saw Revenue skyrocketed 170.0% in 2021 before it fell 10.3% in 2024.
  • A 5-year view of Revenue shows it stood at $143.5 million in 2021, then increased by 8.85% to $156.2 million in 2022, then grew by 17.76% to $184.0 million in 2023, then dropped by 10.3% to $165.0 million in 2024, then rose by 0.61% to $166.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Revenue are $166.0 million (Q4 2025), $149.0 million (Q3 2025), and $172.9 million (Q2 2025).